AI-generated summary
The authors describe a planned randomized, sham-controlled trial testing whether home-based near-infrared photobiomodulation improves cognition in Japanese patients with mild cognitive impairment or mild Alzheimer's dementia. Participants would receive active or sham stimulation three times weekly for 12 weeks, with the primary outcome being change in the ADAS-cognition scale. As a protocol, the paper reports no results yet.
- Participants
- 30
- Who or what was studied
- Japanese patients with mild cognitive impairment or dementia due to Alzheimer's disease
- Limits stated in the abstract
- This is a study protocol with planned sample size of 30 (20 active, 10 sham), so no efficacy or safety results are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Photobiomodulation (PBM) is a novel strategy for cognitive enhancement by improving brain metabolism and blood flow. It is potentially beneficial for patients with Alzheimer's disease (AD). We present a study protocol for a randomised controlled trial designed to evaluate the efficacy and safety of PBM.
Method And Analysis
This is a single-centre, parallel-group, randomised, sham-controlled study. We enroll patients with mild cognitive impairment or dementia due to AD and assigned them to receive either active or sham stimulation at home for 12 weeks, with three sessions per week (20 min each). The stimulation involves invisible near-infrared light delivered by five applicators (one in a nostril, one on the frontal scalp, and three on the occipital scalp). The primary outcome will be the mean change in the Alzheimer Disease Assessment Scale-cognition from baseline to Week 12. We will also measure cognitive function, activity of daily living, behavioral and psychological symptoms, and caregiver burden. We will collect data at clinics at baseline and Week 12 and remotely at home. We estimate a sample size of 30 (20 active and 10 sham) based on an expected mean difference of -6.9 and an SD of 4.8. We use linear models for the statistical analysis. ETHICS AND DISSEMINATION: The National Center of Neurology and Psychiatry Clinical Research Review Board (CRB3200004) approved this study. The results of this study will be published in a scientific peer-reviewed journal. Trial registration details Japan Registry of Clinical Trials jRCTs032230339.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Sham, Mild cognitive impairment, Dementia, Intranasal photobiomodulation, Trial registration, Primary outcome, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.